Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Managing attention-deficit/hyperactivity disorder

Daniel A. Gorman and Elia Abi-Jaoude
CMAJ October 15, 2013 185 (15) E739; DOI: https://doi.org/10.1503/cmaj.121826
Daniel A. Gorman
Department of Psychiatry (Gorman, Abi-Jaoude), University of Toronto; Department of Psychiatry (Gorman), The Hospital for Sick Children; Department of Psychiatry (Abi-Jaoude), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daniel.gorman@sickkids.ca daniel.gorman@utoronto.ca
Elia Abi-Jaoude
Department of Psychiatry (Gorman, Abi-Jaoude), University of Toronto; Department of Psychiatry (Gorman), The Hospital for Sick Children; Department of Psychiatry (Abi-Jaoude), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

See also the Practice article by Jimenez and Guevara at www.cmaj.ca/lookup/doi/10.1503/cmaj.130042

Before starting treatment for attention-deficit/hyperactivity disorder (ADHD), other potential causes for symptoms should be ruled out

Problems with focus and behaviour in some children may occur because of poor sleep, diet (e.g., food additives), hearing or vision impairment, environmental toxins (e.g., lead), learning difficulties, anxiety, depression or family dysfunction.1–4 Symptoms may be developmentally appropriate, especially in young children with late birth dates who are compared with older classmates.5 Diagnostic and Statistical Manual of Mental Disorders criteria for ADHD should be met before treatment is considered.

Nonpharmacological treatments can be effective and should generally be started first

Controlled trials support the efficacy of behavioural therapy for children2 and cognitive–behavioural therapy for adults.6 Lifestyle modifications addressing diet, sleep and exercise may be helpful.7,8

Pharmacotherapy may be appropriate for patients with severe impairment or with insufficient benefit from nonpharmacological treatments

Only stimulants (methylphenidate and amphetamines) and atomoxetine are approved by Health Canada for the treatment of ADHD in adults and children at least 6 years of age. Many placebo-controlled trials support the short-term efficacy of these agents for both age groups,9,10 but evidence for long-term benefit is far more modest. The advantages of stimulants over atomoxetine include rapid onset of action, higher response rate and greater effect size. Atomoxetine may be useful for patients with substance abuse issues, eating disorders or a history of poor responses or tolerability to multiple stimulants.2

Medications for ADHD are generally safe and well tolerated but can have adverse effects and are associated with some small but serious risks

The most common adverse effects are appetite suppression and insomnia with stimulants, sedation and upset stomach with atomoxetine, and mood changes and small increases in heart rate and blood pressure with both types of medication.9,10 Prolonged use of a stimulant typically causes modest growth suppression in children, use of atomoxetine is associated with a small risk of suicidality, and both treatments infrequently cause severe agitation or symptoms of mania or psychosis.2 Because very rare cases of sudden death have been reported in people taking these medications, patients should undergo screening for cardiac risk factors.11

Pharmacotherapy requires frequent monitoring and dose adjustments, especially during the initial titration phase

Stimulants should be started at a low dose and adjusted based on response and adverse effects; atomoxetine should be titrated as tolerated according to a weight-based algorithm. When a stimulant is used, either methylphenidate or an amphetamine can be started; if the response is poor, the other stimulant should be considered next. Monitoring includes evaluating changes in symptoms, functional impairment, adverse effects, body weight and (in children) height, and vital signs.2 Rating scales are available for tracking ADHD symptoms in children2 and adults,12 including some that are available free of charge (e.g., www.adhd.net for children; www.hcp.med.harvard.edu/ncs/asrs.php for adults). Periodic drug-free trials (e.g., annually) should be considered to reassess the need for continued pharmacotherapy.

Footnotes

  • For references, see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121826/-/DC1

  • Competing interests: None declared.

  • This article has been peer reviewed.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (15)
CMAJ
Vol. 185, Issue 15
15 Oct 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Managing attention-deficit/hyperactivity disorder
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Managing attention-deficit/hyperactivity disorder
Daniel A. Gorman, Elia Abi-Jaoude
CMAJ Oct 2013, 185 (15) E739; DOI: 10.1503/cmaj.121826

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Managing attention-deficit/hyperactivity disorder
Daniel A. Gorman, Elia Abi-Jaoude
CMAJ Oct 2013, 185 (15) E739; DOI: 10.1503/cmaj.121826
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Before starting treatment for attention-deficit/hyperactivity disorder (ADHD), other potential causes for symptoms should be ruled out
    • Nonpharmacological treatments can be effective and should generally be started first
    • Pharmacotherapy may be appropriate for patients with severe impairment or with insufficient benefit from nonpharmacological treatments
    • Medications for ADHD are generally safe and well tolerated but can have adverse effects and are associated with some small but serious risks
    • Pharmacotherapy requires frequent monitoring and dose adjustments, especially during the initial titration phase
    • Footnotes
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Plastic bronchitis in a 3-year-old boy
  • Squamous cell carcinoma of the dorsal tongue
  • Thrombotic thrombocytopenic purpura masquerading as a stroke in a young man
Show more Practice

Similar Articles

Collections

  • Topics
    • Psychiatry & mental health: adult
    • Drugs: psychotherapeutic

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire